Venous thromboembolic prophylaxis after elective total hip arthroplasty

Area of Science:

• Orthopaedic Surgery
• Vascular Medicine
• Pharmacology

Background:

• Total hip arthroplasty (THA) significantly improves quality of life but carries a high risk of venous thromboembolic disease (VTE).
• Routine prophylaxis is standard practice for THA patients due to elevated VTE risk.
• Current evidence does not establish a clear preference for specific VTE prophylaxis agents in THA.

Purpose of the Study:

• To review the efficacy and safety of VTE prophylaxis agents used in elective total hip arthroplasty.
• To discuss the impact of reduced hospital stays on prophylaxis duration and screening.
• To guide the selection of optimal VTE prophylaxis regimens for THA patients.

Main Methods:

• Evidence-based review of current VTE prophylaxis agents.
• Analysis of agents including warfarin, low-molecular-weight heparin, fondaparinux, aspirin, and mechanical devices.
• Discussion of factors influencing prophylaxis choice, including patient-specific risks and hospital stay duration.

Main Results:

• Low-molecular-weight heparin, warfarin, and fondaparinux are identified as the most effective prophylactic agents for THA.
• Pneumatic compression devices show efficacy in reducing distal VTE events.
• Further multi-center, randomized studies are needed to confirm mechanical prophylaxis efficacy with short hospital stays.

Conclusions:

• The choice of VTE prophylaxis in THA requires balancing agent efficacy with safety profiles.
• Individual patient factors play a crucial role in determining the most appropriate prophylaxis regimen.
• Optimizing VTE prevention strategies is essential for improving outcomes after total hip arthroplasty.